

**REGISTERED NUMBER: 07142788 (England and Wales)**

**Unaudited Financial Statements**  
**for the Year Ended 31 March 2019**  
**for**  
**Hilary Ellis Pharma Research Ltd**

**Contents of the Financial Statements  
for the Year Ended 31 March 2019**

	<b>Page</b>
<b>Balance Sheet</b>	<b>1</b>
<b>Notes to the Financial Statements</b>	<b>2</b>

**Balance Sheet**  
**31 March 2019**

	Notes	31.3.19 £	31.3.18 £
<b>FIXED ASSETS</b>			
Tangible assets	4	976	1,302
<b>CURRENT ASSETS</b>			
Debtors	5	-	9,602
Investments	6	14,304	28,526
Cash at bank and in hand		<u>19,055</u>	<u>15,593</u>
		33,359	53,721
<b>CREDITORS</b>			
Amounts falling due within one year	7	<u>(3,838)</u>	<u>(6,838)</u>
<b>NET CURRENT ASSETS</b>		<u>29,521</u>	<u>46,883</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>30,497</u>	<u>48,185</u>
<b>CAPITAL AND RESERVES</b>			
Called up share capital		100	100
Retained earnings		<u>30,397</u>	<u>48,085</u>
<b>SHAREHOLDERS' FUNDS</b>		<u>30,497</u>	<u>48,185</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2019.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2019 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of
- (b) Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 5 December 2019 and were signed by:

Miss H J Ellis - Director

**Notes to the Financial Statements  
for the Year Ended 31 March 2019**

**1. STATUTORY INFORMATION**

Hilary Ellis Pharma Research Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address are as below:

<b>Registered number:</b>	07142788
<b>Registered office:</b>	Westminster House 10 Westminster Road Macclesfield Cheshire SK10 1BX

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Turnover**

Turnover is recognised when the company obtains the right to consideration.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Office equipment - 25% on reducing balance

**Pension costs and other post-retirement benefits**

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

**Current asset investments**

Current asset investments are included at the lower of cost or net realisable value.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 1 (2018 - 1).

**4. TANGIBLE FIXED ASSETS**

	Office equipment £
<b>COST</b>	
At 1 April 2018	
and 31 March 2019	<u>4,223</u>
<b>DEPRECIATION</b>	
At 1 April 2018	2,921
Charge for year	<u>326</u>
At 31 March 2019	<u>3,247</u>
<b>NET BOOK VALUE</b>	
At 31 March 2019	<u>976</u>
At 31 March 2018	<u>1,302</u>

Notes to the Financial Statements - continued  
for the Year Ended 31 March 2019

5.	<b>DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR</b>	31.3.19	31.3.18
		£	£
	Trade debtors	<u>-</u>	<u>9,602</u>
6.	<b>CURRENT ASSET INVESTMENTS</b>	31.3.19	31.3.18
		£	£
	Unlisted investments	<u>14,304</u>	<u>28,526</u>
7.	<b>CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR</b>	31.3.19	31.3.18
		£	£
	Taxation and social security	1,801	4,226
	Other creditors	<u>2,037</u>	<u>2,612</u>
		<u>3,838</u>	<u>6,838</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.